Director, Study ClinicianPfizer Inc.Collegeville, Pennsylvania, United States
PB0186 - Results from BeneGene-1 Study: Prospective collection of bleeding rate in hemophilia B patients prior to phase 3 study (BeneGene-2) of fidanacogene elaparvovec
Sunday, June 25, 202318:30 – 19:30 ET
OC 52.3 - Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial
Tuesday, June 27, 202311:15 – 11:30 ET
